827 related articles for article (PubMed ID: 31921562)
21. Alternatives for the treatment of infections caused by ESKAPE pathogens.
da Rosa TF; Coelho SS; Foletto VS; Bottega A; Serafin MB; Machado CS; Franco LN; de Paula BR; Hörner R
J Clin Pharm Ther; 2020 Aug; 45(4):863-873. PubMed ID: 32339305
[TBL] [Abstract][Full Text] [Related]
22. PlyKp104, a Novel Phage Lysin for the Treatment of Klebsiella pneumoniae, Pseudomonas aeruginosa, and Other Gram-Negative ESKAPE Pathogens.
Euler CW; Raz A; Hernandez A; Serrano A; Xu S; Andersson M; Zou G; Zhang Y; Fischetti VA; Li J
Antimicrob Agents Chemother; 2023 May; 67(5):e0151922. PubMed ID: 37098944
[TBL] [Abstract][Full Text] [Related]
23. Quantifying the Evolutionary Conservation of Genes Encoding Multidrug Efflux Pumps in the ESKAPE Pathogens To Identify Antimicrobial Drug Targets.
Brooks LE; Ul-Hasan S; Chan BK; Sistrom MJ
mSystems; 2018; 3(3):. PubMed ID: 29719870
[TBL] [Abstract][Full Text] [Related]
24. Human Salivary Protein Histatin 5 Has Potent Bactericidal Activity against ESKAPE Pathogens.
Du H; Puri S; McCall A; Norris HL; Russo T; Edgerton M
Front Cell Infect Microbiol; 2017; 7():41. PubMed ID: 28261570
[TBL] [Abstract][Full Text] [Related]
25. Detection of ESKAPE Bacterial Pathogens at the Point of Care Using Isothermal DNA-Based Assays in a Portable Degas-Actuated Microfluidic Diagnostic Assay Platform.
Renner LD; Zan J; Hu LI; Martinez M; Resto PJ; Siegel AC; Torres C; Hall SB; Slezak TR; Nguyen TH; Weibel DB
Appl Environ Microbiol; 2017 Feb; 83(4):. PubMed ID: 27986722
[TBL] [Abstract][Full Text] [Related]
26. Progress and challenges in implementing the research on ESKAPE pathogens.
Rice LB
Infect Control Hosp Epidemiol; 2010 Nov; 31 Suppl 1():S7-10. PubMed ID: 20929376
[TBL] [Abstract][Full Text] [Related]
27. Functional Differences between E. coli and ESKAPE Pathogen GroES/GroEL.
Sivinski J; Ambrose AJ; Panfilenko I; Zerio CJ; Machulis JM; Mollasalehi N; Kaneko LK; Stevens M; Ray AM; Park Y; Wu C; Hoang QQ; Johnson SM; Chapman E
mBio; 2021 Jan; 12(1):. PubMed ID: 33436430
[TBL] [Abstract][Full Text] [Related]
28. Selection of Potential Probiotic Bacteria from Exclusively Breastfed Infant Faeces with Antagonistic Activity Against Multidrug-Resistant ESKAPE Pathogens.
Rastogi S; Mittal V; Singh A
Probiotics Antimicrob Proteins; 2021 Jun; 13(3):739-750. PubMed ID: 33190215
[TBL] [Abstract][Full Text] [Related]
29. Evolution of Antimicrobial Resistance Levels of ESKAPE Microorganisms in a Peruvian IV-Level Hospital.
Flores-Paredes W; Luque N; Albornoz R; Rojas N; Espinoza M; Pons MJ; Ruiz J
Infect Chemother; 2021 Sep; 53(3):449-462. PubMed ID: 34508324
[TBL] [Abstract][Full Text] [Related]
30. Recent advances to combat ESKAPE pathogens with special reference to essential oils.
Panda SK; Buroni S; Swain SS; Bonacorsi A; da Fonseca Amorim EA; Kulshrestha M; da Silva LCN; Tiwari V
Front Microbiol; 2022; 13():1029098. PubMed ID: 36560948
[TBL] [Abstract][Full Text] [Related]
31. Bactericidal efficacy of atmospheric pressure non-thermal plasma (APNTP) against the ESKAPE pathogens.
Flynn PB; Higginbotham S; Alshraiedeh NH; Gorman SP; Graham WG; Gilmore BF
Int J Antimicrob Agents; 2015 Jul; 46(1):101-7. PubMed ID: 25963338
[TBL] [Abstract][Full Text] [Related]
32. Differential anti-microbial secondary metabolites in different ESKAPE pathogens explain their adaptation in the hospital setup.
Tiwari V; Meena K; Tiwari M
Infect Genet Evol; 2018 Dec; 66():57-65. PubMed ID: 30227225
[TBL] [Abstract][Full Text] [Related]
33. Retrospective Analysis on Antimicrobial Resistance Trends and Prevalence of β-lactamases in
Nasser M; Palwe S; Bhargava RN; Feuilloley MGJ; Kharat AS
Microorganisms; 2020 Oct; 8(10):. PubMed ID: 33096921
[TBL] [Abstract][Full Text] [Related]
34. Changes in resistance pattern of ESKAPE pathogens between 2010 and 2020 in the clinical center of University of Szeged, Hungary.
Orosz L; Lengyel G; Ánosi N; Lakatos L; Burián K
Acta Microbiol Immunol Hung; 2022 Jan; ():. PubMed ID: 35084364
[TBL] [Abstract][Full Text] [Related]
35. Prevalence of ESKAPE pathogens in the environment: Antibiotic resistance status, community-acquired infection and risk to human health.
Denissen J; Reyneke B; Waso-Reyneke M; Havenga B; Barnard T; Khan S; Khan W
Int J Hyg Environ Health; 2022 Jul; 244():114006. PubMed ID: 35841823
[TBL] [Abstract][Full Text] [Related]
36. Rosin as a Natural Alternative for the effective disinfection of ESKAPE Pathogens and Clostridioides difficile spores.
Bell S; Thompson TP; Marks N; Fairley D; Kettunen H; Vuorenmaa J; Orte J; Gilmore BF; McGrath JW
J Appl Microbiol; 2024 Jan; ():. PubMed ID: 38244225
[TBL] [Abstract][Full Text] [Related]
37. Clinical relevance of the ESKAPE pathogens.
Pendleton JN; Gorman SP; Gilmore BF
Expert Rev Anti Infect Ther; 2013 Mar; 11(3):297-308. PubMed ID: 23458769
[TBL] [Abstract][Full Text] [Related]
38. Update on the main MDR pathogens: prevalence and treatment options.
Esposito S; De Simone G
Infez Med; 2017 Dec; 25(4):301-310. PubMed ID: 29286008
[TBL] [Abstract][Full Text] [Related]
39. Identification of a Specific Biomarker of Acinetobacter baumannii Global Clone 1 by Machine Learning and PCR Related to Metabolic Fitness of ESKAPE Pathogens.
Álvarez VE; Quiroga MP; Centrón D
mSystems; 2023 Jun; 8(3):e0073422. PubMed ID: 37184409
[TBL] [Abstract][Full Text] [Related]
40. Kisameet Clay Exhibits Potent Antibacterial Activity against the ESKAPE Pathogens.
Behroozian S; Svensson SL; Davies J
mBio; 2016 Jan; 7(1):e01842-15. PubMed ID: 26814180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
